Hansa Biopharma to host conference call to provide interim results from Q1 2021 and Business Update
Lund, Sweden April 14, 2021 Hansa Biopharma AB (Nasdaq Stockholm: HNSA) will publish its interim report for January-March 2021 at 8:00 CET on April 22, 2021. All interested parties are invited to participate in a telephone conference, which will include a presentation of the interim results and a business update, on the same date at 14:00 CET/8:00am EST. The event will be hosted by Hansa Biopharma’s CEO, Søren Tulstrup, and CFO, Donato Spota, and the presentation will be held in English.
Slides used in the presentation will be live on the company website during the call under “Events & Webcast,” and will also be made available online after the call. Link to presentation
To participate in the telephone conference, please use the dial-in details provided below:
Sweden: +46 8 50 55 83 75
United Kingdom: +44 333 300 90 35
United States: +1 833 526 83 82
The webcast will be available on https://streams.eventcdn.net/hansa/2021q1/
Updated Calendar and Events 2021
April 22, 2021 Interim report for Jan-Mar 2021
April 28, 2021 Redeye Orphan Drugs Event, Stockholm (virtual)
May 5, 2021 Kempen Life Sciences Conference, Amsterdam (virtual)
May 7+14, 2021 Truist US Roadshow (virtual)
May 11, 2021 Nordnet/Proinvestor Biotech event, Copenhagen (virtual)
May 12, 2021 Annual General Meeting 2021
May 19, 2021 RBC Global Healthcare Conference, NYC (virtual)
May 25, 2021 ABG Life Science Seminar, Stockholm (virtual)
June 1, 2021 Jefferies Healthcare Conference, London (virtual)
June 16, 2021 Citi’s 2021 European Healthcare Conference (virtual)
July 15, 2021 Interim report for Jan-Jun 2021
Aug 25, 2021 Handelsbanken Life Science Innovation Seminar, Stockholm
Sep 1, 2021 Pareto Healthcare Conference, Stockholm (virtual)
Oct 21, 2021 Interim report for Jan-Sep 2021
For further information, please contact:
Klaus Sindahl, Head of Investor Relations
Hansa Biopharma
Mobile: +46 (0) 709-298 269
E-mail: klaus.sindahl@hansabiopharma.com
Katja Margell
Head of Corporate Communications
Hansa Biopharma
Mobile: +46 (0) 768-198 326
E-mail: katja.margell@hansabiopharma.com
About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program, based on the Company’s proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden and has operations in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com.